Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACULAR vs AMMONIUM CHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
Ammonium chloride is an acidifying agent. It dissociates to ammonium and chloride ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which lower blood and urinary p H. It also increases chloride concentration, promoting excretion of bicarbonate and other bases.
Treatment of postoperative inflammation in patients who have undergone cataract extraction,Relief of ocular itching due to seasonal allergic conjunctivitis
Treatment of metabolic alkalosis,Urinary acidification to enhance excretion of weak bases in poisoning,Expectorant (off-label)
One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.
For metabolic alkalosis: 1-2 g orally 3-4 times daily; or 1 g (as 2 mmol/kg) intravenously over 4-6 hours, repeat as needed based on blood gas analysis.
Terminal half-life: 1.8 hours (ketorolac tromethamine); clinical context: short half-life supports dosing every 6 hours for acute pain, but prolonged in elderly or renal impairment (↑ to 5-6 hours, thus dose reduction required).
Terminal elimination half-life is approximately 8-12 hours in normal renal function; prolonged in renal impairment (up to 30 hours) due to reliance on renal acid excretion.
Hepatic metabolism primarily via cytochrome P450 2C9 (CYP2C9).
Ammonium chloride is metabolized in the liver via the urea cycle, where ammonium is converted to urea, consuming bicarbonate and generating hydrogen ions.
Renal: ~80% as unchanged drug and glucuronide conjugates; biliary/fecal: ~20%
Renal: >99% as ammonium ion (NH4+) and chloride (Cl-), with acid excretion via conversion of NH4+ to urea in liver; minimal biliary/fecal.
99% bound; primary binding protein: albumin.
<10% bound to plasma proteins (primarily albumin).
0.11-0.25 L/kg; clinical meaning: low Vd indicates primarily confined to extracellular compartment (plasma and interstitial fluid), minimal tissue penetration.
Approximately 0.3-0.5 L/kg, distributing mainly in extracellular fluid; minimal intracellular penetration.
Ophthalmic: ~2% systemic absorption after topical instillation (due to corneal permeability and nasolacrimal drainage); oral formulation not used for Acular (ophthalmic only).
Oral: 70-80% (subject to first-pass hepatic conversion of NH4+ to urea); intravenous: 100%.
No dosage adjustment required for renal impairment.
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-60 m L/min: reduce dose by 50% and monitor for acidosis. For GFR >60 m L/min: no adjustment necessary.
No dosage adjustment required for hepatic impairment.
No specific Child-Pugh dose adjustments; use with caution in severe hepatic impairment due to risk of encephalopathy.
Safety and efficacy in pediatric patients have not been established; use not recommended.
For metabolic alkalosis: 50-100 mg/kg orally every 6-8 hours, not to exceed 6 g/day. Intravenous: 2-3 mmol/kg over 4-6 hours, repeat based on blood p H.
No specific dosage adjustment required; use same dosing as for younger adults.
Start at low end of dosing range; monitor renal function and electrolytes closely due to age-related decline in GFR.
No FDA boxed warning.
None.
May increase bleeding time due to inhibition of platelet aggregation; use with caution in patients with known bleeding tendencies or those receiving other medications that may prolong bleeding time.,May cause corneal effects including keratitis and corneal thinning; discontinue if corneal epithelial breakdown occurs.,Use with caution in patients with prior sensitivity to aspirin, phenylacetic acid derivatives, or other NSAIDs.,May delay wound healing or exacerbate infections; avoid use in patients with active epithelial herpes simplex keratitis.
May cause metabolic acidosis, hyperammonemia in hepatic impairment, and electrolyte disturbances. Use with caution in patients with renal or hepatic disease, pulmonary insufficiency, or cardiac edema.
Hypersensitivity to ketorolac tromethamine or any component of the formulation,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Active epithelial herpes simplex keratitis,Late pregnancy (third trimester) due to risk of premature closure of ductus arteriosus
Severe hepatic or renal impairment, primary respiratory acidosis, and patients with uremia or high serum bicarbonate levels.
No known food interactions. Avoid alcohol if concomitant oral NSAIDs are used due to increased risk of gastrointestinal bleeding, but this is not specific to ophthalmic use.
Avoid excessive consumption of alkaline foods (e.g., dairy products, fruits) as they may counteract the acidifying effect. Maintain a consistent diet to avoid fluctuations in acid-base balance.
Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairment in the third trimester. First and second trimester use should be avoided unless clearly needed. The potential benefits should be weighed against the risks.
Ammonium chloride is not associated with major human teratogenicity. However, due to its potential to induce metabolic acidosis, high doses may pose theoretical fetal risks, including fetal acidosis and altered fetal p H homeostasis, particularly in the second and third trimesters. No specific trimester-specific risks are well-documented.
Ketorolac is excreted in human milk at low levels. The M/P ratio is not well defined. Due to potential adverse effects in nursing infants, caution is advised. Use only if clearly indicated and consider alternative agents.
Ammonium chloride is excreted into breast milk in small amounts. The M/P ratio is not well-established. At therapeutic doses, exposure to the nursing infant is likely low and not expected to cause adverse effects. Caution is advised with high doses due to potential for maternal acidosis and subsequent infant effects. Consider monitoring infant for signs of acidosis if maternal therapy is prolonged or high-dose.
No specific dose adjustments are recommended for pregnancy; however, use the lowest effective dose for the shortest duration due to potential fetal risks. Physiological changes in pregnancy (increased volume of distribution, renal clearance) may alter pharmacokinetics, but no formal studies justify dose modification.
Pregnancy increases plasma volume and renal clearance, which may reduce the effectiveness of ammonium chloride as an acidifying agent. Higher doses may be required to achieve therapeutic effect, but this must be balanced against the risk of acidosis. No standard dose-adjustment guidelines exist; dosing should be individualized based on maternal acid-base monitoring. Avoid excessive doses that could cause severe acidosis.
ACULAR (ketorolac tromethamine ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) used for ocular inflammation. Avoid concomitant use with other NSAIDs or corticosteroids due to increased risk of corneal adverse events. Use with caution in patients with bleeding disorders or those on anticoagulants, as it may increase bleeding tendency. Monitor for corneal toxicity, especially in patients with compromised corneal integrity. Ensure proper storage at room temperature and discard if solution changes color or becomes cloudy.
Ammonium chloride is used as a systemic acidifying agent to treat metabolic alkalosis. Monitor serum electrolytes and acid-base status closely during therapy. Avoid in severe hepatic or renal impairment. Use with caution in patients with respiratory acidosis.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Apply pressure to the inner corner of the eye (nasolacrimal occlusion) for 1 minute after instillation to reduce systemic absorption.,Do not use while wearing soft contact lenses, as the preservative may be absorbed.,Report any signs of corneal problems such as pain, redness, or vision changes immediately.,Use exactly as prescribed and do not share the medication with others.
Take this medication exactly as prescribed. Do not exceed the recommended dose.,Notify your doctor if you experience nausea, vomiting, confusion, or rapid breathing.,Avoid taking with antacids or alkalinizing agents as they may reduce effectiveness.,Stay hydrated unless otherwise directed by your physician.,Inform your healthcare provider of all medications you are taking, especially diuretics or corticosteroids.
No interactions on record
"Ammonium chloride, an acidifying agent, reduces urinary pH, which increases the renal clearance of lisdexamfetamine and its active metabolite d-amphetamine. This accelerated elimination leads to decreased systemic exposure and potentially diminished therapeutic efficacy of lisdexamfetamine. Clinically, patients may experience reduced symptom control for ADHD or binge eating disorder, requiring dose adjustments or alternative therapies."
"Sufentanil, a potent opioid analgesic, may increase renal excretion of ammonium chloride by promoting diuresis through opioid-induced release of antidiuretic hormone (ADH) and subsequent water reabsorption, leading to dilutional acidosis and enhanced ammonium excretion. This interaction can result in reduced serum ammonium levels and decreased efficacy of ammonium chloride as an acidifying agent, potentially compromising its therapeutic effect in metabolic alkalosis or urinary tract infections. Clinical outcomes may include incomplete correction of metabolic alkalosis or reduced antimicrobial activity of ammonium chloride in the urine."
"Ammonium chloride acidifies the urine, which increases the renal excretion of amphetamine by favoring its ionized form in the tubular lumen, thereby reducing its reabsorption. This leads to a decreased serum concentration of amphetamine and potentially diminished therapeutic efficacy. Clinically, patients may experience reduced mood-elevating or stimulant effects, requiring dose adjustment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACULAR vs AMMONIUM CHLORIDE, answered by our medical review team.
ACULAR is a NSAID Ophthalmic that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.. AMMONIUM CHLORIDE is a Expectorant/Systemic Acidifier that works by Ammonium chloride is an acidifying agent. It dissociates to ammonium and chloride ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which lower blood and urinary p H. It also increases chloride concentration, promoting excretion of bicarbonate and other bases.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACULAR and AMMONIUM CHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACULAR is: One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.. The standard adult dose of AMMONIUM CHLORIDE is: For metabolic alkalosis: 1-2 g orally 3-4 times daily; or 1 g (as 2 mmol/kg) intravenously over 4-6 hours, repeat as needed based on blood gas analysis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACULAR and AMMONIUM CHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACULAR is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairm. AMMONIUM CHLORIDE is classified as Category C. Ammonium chloride is not associated with major human teratogenicity. However, due to its potential to induce metabolic acidosis, high doses may pose theoretical fetal risks, includ. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.